Biogen trims Apellis pipeline and R&D team after $5.6bn takeover - Pharmaceutical Technology

Biogen plans to pause or terminate investment in most of Apellis’ legacy research programmes, while cutting some of its workforce. The pharma company plans to pause or terminate investment in most of Apellis’ legacy research programmes. Biogen is cutting back Apellis’ R&D efforts a little after acquiring the company. Credit: Tada Images / Shutterstock.com. Three months after Biogen announced its $5.6bn buyout of rare disease specialist Apellis Pharmaceuticals, the former has decided to cull most of the biotech’s research pipeline and cut a small number of research staff from the team. This development, which was first reported by Endpoints ,…

Source: Pharmaceutical Technology